Skip to main content
    S

    Silence Therapeutics PLC (SLN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $19.80
    +0.00 (+0.00%)

    Market Cap: $1.23B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Silence Therapeutics PLC (SLN) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Silence Therapeutics (SLN) has a market cap of $1.23B. Its share count is up 250.60% from a year earlier.

    Total Valuation

    Market Cap$1.23B
    Latest price (Nov 17, 2026)$19.80

    Key Dates

    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 250.58% in the quarter ended Sep 30, 2026 and grew 87.58% a year over 2 years.

    Shares Outstanding55.20M
    Shares Change (YoY)+250.60%
    Shares Change (QoQ)+250.58%
    Share Count Growth (2Y CAGR)+87.58%

    Valuation Ratios

    Sales and book value multiples are 882.5x and 5.1x. Its year-end P/S ranged from 2.0x to 104.2x from 2020 to 2025.

    P/S Ratio882.5x
    P/B Ratio5.1x

    Valuation history and multiples

    Price Statistics

    The stock is up 189.90% over 52 weeks and trades 32.98% above its 50-day average.

    Beta (1Y)1.44
    52-Week Change+189.90%
    1-Month Change+1.12%
    3-Month Change+45.48%
    6-Month Change+243.15%
    5-Year Change-10.19%
    Total Return (1Y)+189.90%
    Total Return (3Y CAGR)+29.57%
    Total Return (5Y CAGR)-4.37%
    Return vs SPY (1Y)+181.77%
    Max Drawdown (1Y)-43.75%
    Max Drawdown (3Y)-91.70%
    Sharpe Ratio (1Y)0.95
    Correlation with SPY (1Y)0.17
    50-Day Average$14.89
    200-Day Average$9.93
    52-Week Range$4.19 to $19.86
    RSI (14 Days)77.7
    Average Volume (20 Days)1.49M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 23.94x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio23.94x
    Quick Ratio23.94x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on Assets (ROA)-22.85%
    Receivables Turnover0.11x

    Scores

    SLN has an Altman Z-Score of 7.21, in the safe zone above 2.99, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Altman Z-Score7.21
    Altman Z ZoneSafe
    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About SLN

    What is SLN's market cap?

    Silence Therapeutics has a market cap of $1.23B.

    How many shares of SLN are outstanding?

    Silence Therapeutics has 55.20M shares outstanding. The count is up 250.60% from a year earlier.

    Does SLN pay a dividend?

    No. Silence Therapeutics does not pay a dividend.